Want to see TYRA full AI Analyst Report?
TYRA Stock Chart & Stats
$30.63
$0.43(1.40%)
At close: 4:00 PM EDT
$30.63
$0.43(1.40%)
Day’s Range― - ―
52-Week Range$11.60 - $40.65
Previous Close$31.22
Volume473.79K
Average Volume (3M)370.94K
Market Cap
$1.55B
Enterprise Value$1.76K
Total Cash (Recent Filing)$353.94M
Total Debt (Recent Filing)$5.58M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 11, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding59,676,937
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$49.25Price Target Upside60.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low debt and sizable equity provide structural financial flexibility across clinical programs. Low leverage reduces insolvency risk, supports continued R&D spending without near-term covenant pressure, and gives management options (partnering, opportunistic deals) to finance milestones.
Multi-year Cash RunwayA multi-year cash runway materially lowers near-term financing pressure and supports sequential clinical readouts (e.g., SURF302 data in September). This runway allows management to execute development plans, advance pivotal-enabling studies, and pursue collaborations from a position of strength.
Platform And Targeted PipelineA focused platform targeting FGFR biology and acquired-resistance mechanisms creates scientific differentiation. Multiple investigational candidates diversify program risk, while platform-driven discovery increases odds of follow-on assets and durable competitive positioning in FGFR-driven oncology indications.
Bears Say
Pre-revenue ProfileBeing pre-revenue with large and growing net losses means the company has no operating cash generation to fund operations. Long-term value hinges on successful trials and approvals; until then, progress is financed externally, making outcomes binary and execution-risk sensitive.
Accelerating Cash BurnSteadily accelerating operating cash outflows reflect rising development and operating costs. Persistently negative free cash flow increases the probability of future equity or partnership financing, which can dilute existing holders and shift strategic priorities away from pure science toward near-term funding needs.
Reliance On External Financing & Limited PartnershipsWith no commercial revenue and no disclosed active strategic partnerships, the company depends on capital markets or new collaborations to fund development. This structural dependence heightens exposure to market conditions and may force suboptimal deal terms or dilution before pivotal clinical value is realized.
Tyra Bioscience News
TYRA FAQ
What was Tyra Bioscience’s price range in the past 12 months?
Tyra Bioscience lowest stock price was $11.60 and its highest was $40.65 in the past 12 months.
What is Tyra Bioscience’s market cap?
Tyra Bioscience’s market cap is $1.55B.
When is Tyra Bioscience’s upcoming earnings report date?
Tyra Bioscience’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were Tyra Bioscience’s earnings last quarter?
Tyra Bioscience released its earnings results on Aug 06, 2026. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.04.
Is Tyra Bioscience overvalued?
According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued.
Does Tyra Bioscience pay dividends?
Tyra Bioscience does not currently pay dividends.
What is Tyra Bioscience’s EPS estimate?
Tyra Bioscience’s EPS estimate is -0.69.
How many shares outstanding does Tyra Bioscience have?
Tyra Bioscience has 59,676,937 shares outstanding.
What happened to Tyra Bioscience’s price movement after its last earnings report?
Tyra Bioscience reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went up 4.862%.
Which hedge fund is a major shareholder of Tyra Bioscience?
Currently, no hedge funds are holding shares in TYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tyra Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.25 (60.79% Upside)
$49.25 (60.79% Upside)
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 12.6%
Last 30 Days ▲ 12.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.24%
Trailing 12-Months
Company Description
Tyra Bioscience
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
TYRA Stock 12 Month Forecast
Average Price Target
$49.25
▲(60.79% Upside)
Technical Analysis
Ownership Overview
29.75% Insiders
16.33% Mutual Funds
10.90% Other Institutional Investors
32.89% Public Companies and
Individual Investors